Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis

Friday, March 22, 2019

Lead Pharma a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications today announced that it has achieved a fourth milestone under its license collaboration agreement with Sanofi triggering an undisclosed milestone payment The milestone..

Knopp Biosciences Collaborates with Leading British Researchers to Initiate Phase II Clinical Trial of Dexpramipexole in the Treatment of Severe Eosinophilic Asthma

Friday, March 22, 2019

Knopp Biosciences LLC a private drug discovery and development company dedicated to providing breakthrough treatments for inflammatory and neurological diseases with high unmet medical needs announced today a collaboration with a consortium of leading medical researchers in the UK to evaluate the ab..

Primex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN in France

Friday, March 22, 2019

Nordic Group a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products and Primex Pharmaceuticals AG an innovative global Anaesthesia pharmaceutical company announced a strategic agreement today to launch OZALIN in France One of the challenges faci..

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimers Disease

Friday, March 22, 2019

Biogen and Eisai Co Ltd announced the decision to discontinue the global Phase 3 trials ENGAGE and EMERGE designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer39s disease and mild Alzheimer39s disease dementia The decision to stop the ..

AlzProtect Starts Collaboration with PAREXEL Biotech for Phase 2a of AZP2006 for the Treatment of Progressive Supranuclear Palsy PSP

Friday, March 22, 2019

ALZPROTECT a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer39s disease today announced that PAREXEL Biotech a new division of PAREXEL International Corporation has been selected to perform the clinical phase 2a development of AZP2006 for the treatment of..

Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for ComplementMediated Diseases

Thursday, March 21, 2019

Alexion Pharmaceuticals Inc and Zealand Pharma AS today announced a collaboration to discover and develop novel peptide therapies for complementmediated diseases Peptides offer a number of advantages including being highly selective and potent allowing low dosage volumes for ease of administration a..

ValoremRx Collaborates with Kroger Specialty Pharmacy to Improve Access and Patient Care

Thursday, March 21, 2019

ValoremRx Specialty Solutions the group purchasing organization GPO formed by a joint venture between Express Scripts and Walgreens today announced its new collaboration with Kroger Specialty Pharmacy Partnered with Express Scripts39 specialty pharmacy Accredo and Walgreens39 specialty pharmacy affi..

Aptar Pharmas Bidose Nasal Drug Delivery Device Approved by US FDA for Breakthrough Treatment of Depression

Wednesday, March 20, 2019

Aptar Pharma a leading drug delivery systems provider is pleased to announce that its Bidose nasal spray device was recently approved by the US FDA for a breakthrough therapy in the field of depression This marks the first FDA approval and US launch of a prescription drug using Aptar Pharmas patente..

SOTIOs DCVACOvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer

Wednesday, March 20, 2019

SOTIO a biotechnology company owned by the PPF Group presented results from SOV02 its Phase II clinical trial evaluating DCVACOvCa an active cellular immunotherapy product in patients with recurrent ovarian cancer at 2019 SGOs 50th Annual Meeting on Women39s Cancer today Final analysis of SOV02 show..

Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases

Wednesday, March 20, 2019

Abzena the global biologics gene to GMP partner research organization announced it has signed an agreement to support an integrated CMC program with Lipum a company developing treatments for chronic inflammatory diseases Abzena will support Lipums antiBSSL antibody IND program to help develop a n..

Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly

Wednesday, March 20, 2019

Crinetics Pharmaceuticals Inc a clinical stage pharmaceutical company focused on the discovery development and commercialization of novel therapeutics for rare endocrine diseases and endocrinerelated tumors today announced the dosing of the first patients in the ACROBAT EVOLVE and EDGE trials for CR..

Domainex and SpiroChem Enter a Fragment Drug Discovery Partnership

Wednesday, March 20, 2019

Domainex Ltd an integrated provider of drug discovery services that has established a worldleading position in fragmentbased drug discovery and SpiroChem AG a premium chemical and services companies specialized in the design and synthesis of proprietary collections of sp3rich molecular fragments and..

Turkish Cargo sponsored the carriage of historical artifacts from the Topkapi and Dolmabahe Palaces to Japan

Wednesday, March 20, 2019

Turkish Cargo the air cargo brand of Turkish Airlines that provides service to 124 countries carried 186 historical artifacts owned by Dolmabahe and Topkapi Palaces to Tokyo the capital of Japan as the sponsor carrier in order to be displayed at the exhibition titled as The Ottoman Empire and Tulip ..

China National Biotec Group CNBG and ImmunoBiology Ltd Enter Licensing Agreement to CoDevelop Next Generation Vaccine against Pneumococcal Disease in Greater China

Tuesday, March 19, 2019

ImmunoBiology Ltd ImmBio a vaccine RD company based at Babraham Research Campus near Cambridge UK has recently signed a licensing agreement with LIBP Lanzhou Institute of Biological Product a subsidiary company under CNBG This partnership will enable ImmBio and LIBP to codevelop ImmBios proprieta..

Aptar Pharmas Bidose Nasal Drug Delivery Device Approved by US FDA for Breakthrough Treatment of Depression

Tuesday, March 19, 2019

Aptar Pharma a leading drug delivery systems provider is pleased to announce that its Bidose nasal spray device was recently approved by the US FDA for a breakthrough therapy in the field of depression This marks the first FDA approval and US launch of a prescription drug using Aptar Pharmas patente..

Pharmapack success points to sizeable growth potential for global drug delivery and packaging in 2019

Tuesday, March 19, 2019

The drug delivery and healthcare packaging industry is set for significant growth in 2019 as Pharmapack Europe pharmapackeu a key bellwether of industry health welcomed a record 410 exhibiting companies and nearly 5500 attendees from 75 countries Europes biggest pharmaceutical packaging and drug d..

Highlighting Advantages of the Wholeindustrychain Layout Starting the New Journey of Internationalization of Pharmaceuticals

Tuesday, March 19, 2019

Some API enterprises have gradually shifted their RD and production focuses to the high valueadded characteristic APIs and customized APIs and intermediates in recent years under the influence of the increasingly tightened environmental protection policy and decline of export prices due to excess ca..

Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials

Monday, March 18, 2019

Xynomic Pharma a clinical stage USChina oncology drug development company and Bison Capital Acquisition Corp Nasdaq BCAC today jointly announced that China Spain and Poland authorities have approved Xynomic39s application to conduct potentially pivotal Phase 3 trial using Xynomic39s abexinostat in c..

Cellesce Announces License Agreement with Hubrecht Organoid Technology HUB for the Expansion of Breast Cancer Organoids at Scale

Monday, March 18, 2019

Cellesce and Hubrecht Organoid Technology HUB have today announced a licence agreement for the expansion of organoids using Cellesces own bioprocessing technology and HUB Organoid Technology for the scale up of breast organoids Cellesce and HUB have an ongoing agreement for the expansion of organ..

Pii to Manufacture FDAapproved Busulfan Injection Drug Product

Saturday, March 16, 2019

Pharmaceutics International Inc Pii a Contract Development and Manufacturing Organization CDMO headquartered in Hunt Valley Maryland is pleased to announce the launch of Busulfan Injection 6mgmL in 10mL vials in partnership with Athenex Pharmaceuticals Sungen Pharma and Chemwerth Pii is responsible ..